BAX vs TFX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BAX is the larger of the two ($12.35B market cap): the incumbent the market prices for continued execution (11.68x forward earnings, beta 0.67). TFX is the smaller challenger ($5.97B), priced similarly on forward earnings (12.88x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BAX vs TFX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BAX | TFX | What it tells you |
|---|---|---|---|
| Market cap | $12.35B | $5.97B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 11.68 | 12.88 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.67 | 0.83 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 57% of range | 91% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.90 | 2.06 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BAX and TFX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and TFX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and TFX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Baxter International (BAX) do?
Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.
What does Teleflex Incorporated (TFX) do?
Teleflex Incorporated designs and manufactures single-use medical devices used in critical care and surgery, sold mainly to hospitals through a large disposable-product installed base. After a portfolio overhaul announced in 2025 and executed through 2026, the continuing business reports in three segments: Vascular Access (the Arrow line of central venous and arterial catheters and related kits), Interventional (complex catheters, the MANTA large-bore closure device, intra-aortic balloon pumps, and the newly acquired Biotronik coronary and peripheral range including the ultrathin Orsiro Mission drug-eluting stent, the PK Papyrus covered stent, and the Pantera Lux and Passeo-18 Lux drug-coated balloons), and Surgical (ligation clips, closure systems, and instruments). The businesses being sold, Acute Care, Interventional Urology (home of UroLift), and OEM contract manufacturing, are reported as discontinued operations.
BAX vs TFX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
- TFX drivers: Biotronik vascular intervention integration; Portfolio simplification and capital returns.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For TFX, the Acute Care and Interventional Urology sale to Intersurgical drew a Federal Trade Commission second request in March 2026, so that leg of the divestiture carries real timing and completion risk even though the OEM sale cleared.
BAX or TFX: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAX if you believe its drivers more; TFX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and TFX guides.
BAX vs TFX: the full fundamentals
BAX. Baxter trades at about 12.6 times forward earnings and roughly 1.2 times sales, a modest valuation for medtech that reflects its low-growth profile and the debt load, even after a 31% rally in 2026. Reported GAAP profit is still negative over the trailing year because of special charges, so adjusted metrics and the coming October 29 report (consensus about $0.52 per share) carry most of the weight.
TFX. Trailing P/E is not meaningful because GAAP earnings are still negative on divestiture and impairment charges, so the market prices Teleflex off adjusted EPS and forward estimates. At roughly ~$130 the shares sit mid-range in a ~$100 to ~$145 fifty-two week band and trade near ~12x consensus 2027 EPS, below where large-cap medtech peers typically trade. Third quarter 2026 results are due October 29, 2026, with consensus near ~$1.89 of adjusted EPS on ~$565 million of revenue.
Headline figures (approximate, October 2026): BAX shows revenue (ttm) ~$11.5B, q2 2026 sales ~$2.96B, up ~5% year over year, q2 2026 adjusted eps ~$0.56 vs ~$0.37 expected, operating margin (ttm) ~14%; TFX shows revenue (ttm) ~$2.25B (+~29% yoy in Q2, Biotronik-boosted), q2 2026 revenue ~$570M; adj. EPS ~$1.76 vs ~$1.28 est., margins (gross / operating) ~55% / ~10%, eps (trailing gaap / 2026 est.) ~-$8.48 / ~$7.08.
The bottom line: BAX vs TFX
BAX and TFX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and TFX exposure against your real portfolio. It is not an investment adviser.
Wondering how BAX or TFX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Baxter International with AI
Connect the broker you already use and ask Walnut's AI how BAX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BAX and TFX?
+
Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. Teleflex Incorporated designs and manufactures single-use medical devices used in critical care and surgery, sold mainly to hospitals through a large disposable-product installed base. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BAX or TFX the better stock?
+
Neither is universally better. BAX is the larger incumbent; TFX is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BAX or TFX?
+
On forward P/E (as of November 2026), BAX trades at 11.68x and TFX at 12.88x, so BAX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BAX and TFX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BAX vs TFX?
+
BAX: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $9.7 billion in total as of June 2026) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure, and the company still shows a GAAP net loss of roughly $968 million over the trailing twelve months. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. After a 31% rally, expectations are higher going into the third quarter, Wall Street's average rating is hold, and the average target of about $27.92 sits only modestly above the share price. The turnaround is early and could take longer than management projects. TFX: The Acute Care and Interventional Urology sale to Intersurgical drew a Federal Trade Commission second request in March 2026, so that leg of the divestiture carries real timing and completion risk even though the OEM sale cleared. GAAP results are negative on a trailing twelve month basis (trailing EPS near negative ~$8.48, with fourth quarter 2025 alone showing a ~$714 million loss) because of divestiture and impairment charges, which makes trailing earnings metrics unusable and forces reliance on adjusted figures. Integration risk from the Biotronik deal is meaningful: coronary stents and drug-coated balloons compete head-on with Abbott, Boston Scientific, Medtronic and Terumo, all of which are larger and have deeper clinical evidence programs. The company is led by an interim chief executive, and a permanent hire could revisit strategy or guidance. Beyond that, hospital procedure volumes, reimbursement pressure, tariffs, currency, and the ~$90 million stranded-cost overhang all bear on whether 2026 adjusted EPS lands near the ~$7.08 analyst consensus. Leverage is also meaningful until divestiture proceeds arrive: total debt was roughly ~$2.9 billion against ~$324 million of cash at the end of June 2026.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BAX or TFX; figures are approximate and dated (as of November 2026). Verify current data before investing.